Clinical trials: sponsored by University of Calgary
Stroke, Acute
Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis
The primary purpose of this study is to determine if a single dose of nerinetide can reduce global disability in people who have had a stroke and are selected for endovascular therapy without the use of a tissue plasminogen…
- Trial name
- ESCAPE-NEXT (NCT04462536)
- Testing
- Nerinetide
- Where
- 81 sites in United States, Australia and 7 more
- Volunteers
- 850 people
- Sponsor
- NoNO Inc.
Stroke, Acute
Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke
The ESCAPE-NA-1 study is designed to determine the safety and efficacy of the neuroprotectant, Nerinetide (NA-1), in reducing global disability in subjects with major acute ischemic stroke (AIS) with a small established infarct…
- Trial name
- ESCAPE-NA1 (NCT02930018)
- Testing
- Nerinetide (NA-1), 2.6 mg/kg
- Where
- 50 sites in United States, Australia and 6 more
- Volunteers
- 1,105 people
- Sponsor
- NoNO Inc.